Frequently Asked Questions
The market is segmented based on , By Sequencing Technology (High-Throughput Sequencing, Sanger Sequencing, SBL, RNA Sequencing, SBS, Third-Generation Sequencing, Whole Genome Sequencing, Targeted Gene Sequencing, Shotgun Sequencing, Others), Component (Reagents & Kits, Instruments), Targeted Disease (CNS Diseases, Gastrointestinal Diseases, Oncology, Infectious Diseases, Others), Application (Personalized Medicine, Genetic Screening, Therapeutic, Drug & Biomarker Discovery, Disease Diagnosis Research, Others), Research Type (Outsourced, In-House), End-User (Pharmaceutical & Biotechnology, Academic Centers & Research Institutes, CROs, Others), Laboratory Type (Dry Lab, Wet Lab) – Industry Trends and Forecast to 2030.
.
The Global Microbiome Sequencing Market size was valued at USD 1204.15 USD Million in 2022.
The Global Microbiome Sequencing Market is projected to grow at a CAGR of 18.7% during the forecast period of 2023 to 2030.
The major players operating in the market include CosmosID, Charles River Laboratories, Diversigen, Illumina, Metabiomics Corp., Oxford Nanopore Technologies, BaseClear B.V., BGI, BioMathematica, Microbiome Therapeutics Innovation Group, Clinical, Microbiomics A/S, Eurofins Scientific, LABCYTE , Leucine Rich Bio , Microbiome Insights, Zymo Research Corporation, Thermo Fisher Scientific , Molzym GmbH & Co. KG, Norgen Biotek Corp., Phase Genomics .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
